Publication & Citation Trends
Publications
0 total
A phase 2 study of lanreotide as a therapy for pheochromocytomas (PCs) and paragangliomas (PGs).
Cited by 1
Semantic Scholar
Abstract 6314: Development of g-rate based random forest machine learning model to predict overall survival for patients with metastatic prostate cancer
Cited by 0
Semantic Scholar
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan OA
Cited by 2
Semantic Scholar
Comparison of PSA-based g -rate and conventional PSA metrics in veterans with metastatic prostate cancer (mPC).
Cited by 0
Semantic Scholar
CheMo4METPANC: Combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreatic adenocarcinoma—Updated clinical and translational findings.
Cited by 2
Semantic Scholar
g -Rate–based machine learning model to predict overall survival (OS) in patients with metastatic prostate cancer (mPC) while on treatment.
Cited by 0
Semantic Scholar
Contribution of neoadjuvant chemotherapy and radiation therapy (intensity-modulated radiation therapy with concurrent chemotherapy versus stereotactic body radiation therapy alone) on tumor volume regression in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma:
Cited by 0
Semantic Scholar
CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma.
Cited by 1
Semantic Scholar
A Phase I Study of a Combination of Liposomal Irinotecan and Veliparib in Solid Tumors. OA
Cited by 6
Semantic Scholar
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
Cited by 2
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(1)
HER2/EGFR in Cancer Research
(1)
Analytical Chemistry and Chromatography
(1)
Colorectal Cancer Treatments and Studies
(1)
Sphingolipid Metabolism and Signaling
(1)
Affiliations
American Society of Clinical Oncology
Massachusetts General Hospital
Kennedy Memorial Hospital